Latanoprost/Timolol Blumont Pharma (Timolol Maleate, Latanoprost)

The combination contains latanoprost, which activates prostaglandin F receptors to increase uveoscleral outflow of aqueous humor, and timolol, a non‑selective β‑blocker that reduces aqueous humor production by blocking β‑adrenergic receptors in the ciliary epithelium. Together they produce a greater pressure‑lowering effect than either component alone.

The prescribed dose is determined by the treating ophthalmologist. Typically, one drop is instilled in the affected eye(s) once daily in the evening, but the exact regimen should follow the clinician’s instructions and may be adjusted based on individual response.

Safety data in pregnancy and lactation are limited. The product should only be used if the potential benefit justifies any possible risk to the fetus or infant. Women who are pregnant, planning pregnancy, or breastfeeding should discuss alternatives with their healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Compared with single‑agent therapy, the fixed‑dose combination offers additive intra‑ocular pressure reduction, often achieving target pressures with a single daily drop. This can improve adherence and reduce exposure to multiple preservatives, while providing comparable safety to each component used alone.

Store the ophthalmic solution at ambient temperature, away from direct sunlight and moisture. Keep the bottle tightly closed in its original packaging until use. Do not freeze the product, and discard any solution that appears discolored or contains particles.

The medication is applied topically to the eye. Tilt the head back, pull down the lower eyelid to create a small pocket, and place one drop into the conjunctival sac. Close the eye gently for a few seconds, avoid blinking excessively, and do not touch the tip of the bottle to the eye or any surface.

Serious adverse events, although rare, include severe allergic reactions (e.g., anaphylaxis), persistent ocular inflammation such as uveitis or keratitis, and systemic effects like marked bradycardia or bronchospasm, especially in patients with underlying respiratory or cardiac disease.

Patients with active ocular infections or inflammation, known hypersensitivity to prostaglandin analogues or beta‑blockers, and individuals with severe asthma, chronic obstructive pulmonary disease, or certain cardiac conduction disorders should avoid this medication unless a specialist determines that benefits outweigh risks.